Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary F Fitzgerald

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Opinion in Pharmacology|April 10, 2009
The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPDJ Craig Fox, Mary F Fitzgerald
Drug Discovery Today|May 29, 2007
Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical developmentMary F Fitzgerald, J Craig Fox
Pharmacogenomics|April 30, 2003
Etiologics ltdDavid A Campbell, Mary F Fitzgerald
Drug Discovery Today|May 29, 2007
Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapiesMary F Fitzgerald, J Craig Fox
The Journal of Pharmacology and Experimental Therapeutics|December 7, 2007
p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammationSatyanarayana Medicherla, Mary F Fitzgerald, Dianne Spicer, et al.
Respiratory Research|April 14, 2026
Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)Tania Hugo, Andrew R Harper, Jacob Leander, et al.
The Journal of Allergy and Clinical Immunology|January 2, 2023
Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthmaGabriele Matschiner, Mary F Fitzgerald, Ulrich Moebius, et al.
Chemmedchem|June 18, 2015
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary DiseasesFranz von Nussbaum, Volkhart M-J Li, Swen Allerheiligen, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|November 5, 2024
Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstructionKatharina Heinzelmann, Athanasios Fysikopoulos, Thomas J Jaquin, et al.
Nature Communications|April 4, 2025
Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatmentVanessa Neiens, Eva-Maria Hansbauer, Thomas J Jaquin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Opinion in Pharmacology|April 10, 2009
The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPDJ Craig Fox, Mary F Fitzgerald
Drug Discovery Today|May 29, 2007
Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical developmentMary F Fitzgerald, J Craig Fox
Pharmacogenomics|April 30, 2003
Etiologics ltdDavid A Campbell, Mary F Fitzgerald
Drug Discovery Today|May 29, 2007
Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapiesMary F Fitzgerald, J Craig Fox
The Journal of Pharmacology and Experimental Therapeutics|December 7, 2007
p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammationSatyanarayana Medicherla, Mary F Fitzgerald, Dianne Spicer, et al.
Respiratory Research|April 14, 2026
Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)Tania Hugo, Andrew R Harper, Jacob Leander, et al.
The Journal of Allergy and Clinical Immunology|January 2, 2023
Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthmaGabriele Matschiner, Mary F Fitzgerald, Ulrich Moebius, et al.
Chemmedchem|June 18, 2015
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary DiseasesFranz von Nussbaum, Volkhart M-J Li, Swen Allerheiligen, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|November 5, 2024
Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstructionKatharina Heinzelmann, Athanasios Fysikopoulos, Thomas J Jaquin, et al.
Nature Communications|April 4, 2025
Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatmentVanessa Neiens, Eva-Maria Hansbauer, Thomas J Jaquin, et al.
Pageof 1